A Novel Strategy to Prevent Advanced Atherosclerosis and Lower Blood Glucose in a Mouse Model of Metabolic Syndrome
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Cardiovascular disease caused by atherosclerosis is the leading cause of mortality associated with type 2 diabetes and metabolic syndrome. Insulin therapy is often needed to improve glycemic control, but it does not clearly prevent atherosclerosis. Upon binding to the insulin receptor (IR), insulin activates distinct arms of downstream signaling. The IR-Akt arm is associated with blood glucose lowering and beneficial effects, whereas the IR-Erk arm might exert less desirable effects. We investigated whether selective activation of the IR-Akt arm, leaving the IR-Erk arm largely inactive, would result in protection from atherosclerosis in a mouse model of metabolic syndrome. The insulin mimetic peptide S597 lowered blood glucose and activated Akt in insulin target tissues, mimicking insulin’s effects, but only weakly activated Erk and even prevented insulin-induced Erk activation. Strikingly, S597 retarded atherosclerotic lesion progression through a process associated with protection from leukocytosis, thereby reducing lesional accumulation of inflammatory Ly6Chi monocytes. S597-mediated protection from leukocytosis was accompanied by reduced numbers of the earliest bone marrow hematopoietic stem cells and reduced IR-Erk activity in hematopoietic stem cells. This study provides a conceptually novel treatment strategy for advanced atherosclerosis associated with metabolic syndrome and type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772 · cited 1×
“Although S597 inhibited the effect of insulin on Akt activation in the nonatherosclerotic aorta in vivo, that this action significantly contributed to the antiatherosclerotic effect of S597 is unlikely because vascular Akt1, the main Akt isoform expressed in endothelial cells and smooth muscle cells (45), prevents ath…”
BackgroundTacke, F., Alvarez, D., Kaplan, T. J., Jakubzick, C., Spanbroek, R., Llodra, J., Garin, A., Liu, J., Mack, M., van Rooijen, N., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28549 · Cited by 1,323 · cited 2×
“On one hand, Ly6C monocytes are monocytes recruited from the bone marrow in response to inflammatory stimuli, and this population readily enters lesions of atherosclerosis (19).”
BackgroundMethodLi, S., Brown, M. S., & Goldstein, J. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914798107 · Cited by 733 · cited 1×
“Although a functional bifurcation of signaling events downstream of Akt has been shown to regulate hepatic lipogenesis versus gluconeogenesis (10), the relative roles of IR-induced Akt and Erk pathways on atherosclerosis are unknown.”
BackgroundBiddinger, S. B., Hernandez-Ono, A., Rask-Madsen, C., Haas, J. T., Alemán, J. O., Suzuki, R., Scapa, E. F., Agarwal, C., Carey, M. C., Stephanopoulos, G., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.013 · Cited by 469
Nonclassical Patrolling Monocyte Function in the Vasculature
Thomas, G., Tacke, R., Hedrick, C. C., & Hanna, R. N. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304650 · Cited by 367
Lewis, K. E., Kirk, E. A., McDonald, T. O., Wang, S., Wight, T. N., O’Brien, K. D., & Chait, A. (2004) · Circulation · doi:10.1161/01.cir.0000136819.93989.e1 · Cited by 163 · cited 2×
“Plasma serum amyloid A levels were measured as described previously (21).”
MethodSelf-citationAverill, M. M., Barnhart, S., Becker, L., Li, X., Heinecke, J. W., LeBoeuf, R. C., Hamerman, J. A., Sorg, C., Kerkhoff, C., & Bornfeldt, K. E. (2011) · Circulation · doi:10.1161/circulationaha.110.985523 · Cited by 155 · cited 2×
“Glucose- and insulin-tolerance tests were performed as described (17).”
BackgroundMethodSelf-citationTreatment of dyslipidemia in diabetes: recent advances and remaining questions
Chait, A., & Goldberg, I. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0942-8 · Cited by 40 · cited 1×
“4G), suggesting that triglyceride lowering does not explain the reduced atherosclerosis in S597-treated mice, consistent with the inconclusive results of triglyceride-lowering on CVD in humans (35).”
ResultSelf-citation
Cited by
Ouimet, M., Barrett, T. J., & Fisher, E. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.312617 · Cited by 761
Evans, M., Welsh, Z., Ells, S., & Seibold, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00720-0 · Cited by 185
Monocytes and macrophages as protagonists in vascular complications of diabetes
Kanter, J. E., Hsu, C.-C., & Bornfeldt, K. E. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00010 · Cited by 76
Self-citationTuning insulin receptor signaling using de novo-designed agonists
Wang, X., Cardoso, S., Cai, K., Venkatesh, P., Hung, A., Ng, M., Hall, C., Coventry, B., Lee, D. S., Chowhan, R., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.09.020 · Cited by 24
“35,41,42 Designed agonists modulate IR autophosphorylation, trafficking, and proliferation When insulin activates the IR, several tyrosine residues in the jux-tamembrane (e.g., Y960), kinase (e.g., Y1146, Y1150, and Y1151), and CT domains (e.g., Y1316 and Y1322) undergo trans-autophosphorylation…”
Metadata
- Authors
- Kanter, J. E., Kramer, F., Barnhart, S., Duggan, J. M., Shimizu-Albergine, M., Kothari, V., Chait, A., Bouman, S. D., Hamerman, J. A., Hansen, B. F., Olsen, G. S., & Bornfeldt, K. E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-02-26
- Volume
- 67
- Issue
- 5
- Pages
- 946-959
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2792325770
- Cited by
- 38
- References
- 8
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.